Cellectar Biosciences (CLRB) Net Income (2010 - 2026)
Cellectar Biosciences (CLRB) posted Net Income of -$5.8 million for Q4 2025, down 16.76% sequentially from -$5.0 million in Q3 2025, and up 95.14% YoY from -$3.0 million in Q4 2024.
Cellectar Biosciences (CLRB) Net Income (2010 - 2026) Analysis & Trends
Cellectar Biosciences has reported Net Income for 16 years, with the latest figure at -$5.8 million in Q4 2025.
- Quarterly Net Income rose 95.14% year-over-year to -$5.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$24.0 million (up 85.12% YoY) and the FY2025 annual result came in at -$21.7 million, up 38.37% from the prior year.
- Net Income slipped to -$5.8 million in Q4 2025 per CLRB's latest filing, from -$5.0 million in the prior quarter.
- Over five years, Net Income peaked at -$5.0 million in Q3 2025 and troughed at -$120.2 million in Q4 2024.
- A 5-year average of -$17.7 million and a median of -$7.7 million in 2022 frame the typical range for Net Income.
- The sharpest annual moves came in 2022 and 2025: Net Income tumbled 1205.38% in 2022, then surged 95.14% in 2025.
- Over 5 years, Net Income stood at -$6.2 million in 2021, then sank by 1205.38% to -$80.3 million in 2022, then soared by 82.29% to -$14.2 million in 2023, then slumped by 744.87% to -$120.2 million in 2024, then soared by 95.14% to -$5.8 million in 2025.
- According to Business Quant data, Net Income over the past three periods registered -$5.8 million, -$5.0 million, and -$6.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.92 Bn | 131.07 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.91 Bn | 77.91 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.87 Bn | 59.68 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.18 Bn | 53.04 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.96 Bn | 36.87 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.23 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 27.79 Bn | 9.40 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.37 Bn | 26.53 Bn | - | 81.49 Mn |
| 10 | Cellectar Biosciences | 6.72 Mn | 6.72 Mn | - | -7.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.34 Mn |
| Dec 31, 2025 | -5.85 Mn |
| Sep 30, 2025 | -5.01 Mn |
| Jun 30, 2025 | -6.62 Mn |
| Mar 31, 2025 | -6.56 Mn |
| Dec 31, 2024 | -120.23 Mn |
| Sep 30, 2024 | -14.02 Mn |
| Jun 30, 2024 | -14.43 Mn |
| Mar 31, 2024 | -12.77 Mn |
| Dec 31, 2023 | -14.23 Mn |
| Sep 30, 2023 | -9.67 Mn |
| Jun 30, 2023 | -8.57 Mn |
| Mar 31, 2023 | -8.85 Mn |
| Dec 31, 2022 | -80.35 Mn |
| Sep 30, 2022 | -8.03 Mn |
| Jun 30, 2022 | -7.44 Mn |
| Mar 31, 2022 | -6.14 Mn |
| Dec 31, 2021 | -6.15 Mn |
| Sep 30, 2021 | -6.19 Mn |
| Jun 30, 2021 | -6.44 Mn |